The Effect of Acclydine in Chronic Fatigue Syndrome: A Randomized Controlled Trial
Open Access
- 18 May 2007
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Clinical Trials
- Vol. 2 (5), e19
- https://doi.org/10.1371/journal.pctr.0020019
Abstract
It is unclear whether insulin-like growth factor (IGF) function is involved in the pathophysiology of chronic fatigue syndrome (CFS). Unpublished data and reports in patient organization newsletters suggest that Acclydine, a food supplement, could be effective in the treatment of CFS by increasing biologically active IGF1 levels. Here we aimed to measure the IGF1 and IGF binding protein (IGFBP) 3 status of CFS patients compared to age- and gender-matched neighborhood controls, and to assess the effect of Acclydine on fatigue severity, functional impairment, and biologically active IGF1 level (IGFBP3/IGF1 ratio). A randomized, placebo-controlled, double-blind clinical trial. Radboud University Nijmegen Medical Centre, The Netherlands. Fifty-seven adult patients who fulfilled the US Centers for Disease Control and Prevention criteria for CFS. IGF status of 22 CFS patients was compared to that of 22 healthy age- and gender-matched neighborhood control individuals. Acclydine or placebo for 14 wk. Outcomes were fatigue severity (Checklist Individual Strength, subscale fatigue severity [CIS-fatigue]), functional impairment (Sickness Impact Profile-8 [SIP-8]), and biologically active IGF1 serum concentrations. Analyses were on an intention-to-treat basis. There was no difference in IGF status in 22 CFS patients compared to healthy age- and gender-matched control individuals. Treatment with Acclydine did not result in significant differences compared with the placebo group on any of the outcome measures: CIS-fatigue +1.1 (95% CI −4.4 to +6.5, p = 0.70), SIP-8 +59.1 (95% CI −201.7 to +319.8, p = 0.65), and IGFBP3/IGF1 ratio −0.5 (95% CI −2.8 to +1.7, p = 0.63). We found no differences in IGF1 status in CFS patients compared to healthy matched neighborhood controls. In addition, the results of this clinical trial do not demonstrate any benefit of Acclydine over placebo in the treatment of CFS. Controlled-Trials.com ISRCTN77271661Keywords
This publication has 24 references indexed in Scilit:
- Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic reviewJournal of the Royal Society of Medicine, 2006
- The Placebo Response in the Treatment of Chronic Fatigue Syndrome: A Systematic Review and Meta-AnalysisPsychosomatic Medicine, 2005
- Fatigue among working people: validity of a questionnaire measureOccupational and Environmental Medicine, 2000
- The quality of life of adults with growth hormone deficiency: comparison with diabetic patients and control subjectsClinical Endocrinology, 1999
- Changes in growth hormone, insulin, insulinlike growth factors (IGFs), and IGF-binding protein-1 in chronic fatigue syndromeBiological Psychiatry, 1997
- Somatomedin C (insulin-like growth factor I) levels in patients with chronic fatigue syndromeJournal of Psychiatric Research, 1997
- Clinical Aspects of Growth Hormone Deficiency in AdultsEndocrine Reviews, 1995
- The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and StudyAnnals of Internal Medicine, 1994
- Dimensional assessment of chronic fatigue syndromeJournal of Psychosomatic Research, 1994
- The Sickness Impact Profile: Development and Final Revision of a Health Status MeasureMedical Care, 1981